First participants dosed in Dicot's phase 1 trial
Press release: Uppsala, September 4, 2023. The potency drug developer Dicot announces today that the first study participants have been dosed in the company's clinical phase 1 trial.Dicot has recently started the first clinical trial with its potency drug candidate LIB-01. The primary objective of the study is to evaluate the safety of LIB-01 and consists of two parts: single dosing and repeated dosing. The recruitment of healthy participants for the first part of the study, the single dosing, started immediately after approval from the authorities and today the first participants have been